Hypertrophic obstructive cardiomyopathy: alcohol septal ablation by Fifer, Michael A. & Sigwart, Ulrich
REVIEW
Controversies in cardiovascular medicine
Hypertrophic obstructive cardiomyopathy:
alcohol septal ablation
Michael A. Fifer1 and Ulrich Sigwart2*
1Cardiology Division, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, 55 Fruit Street, Gray/Bigelow Building, Suite 800, Boston, MA 02114,
USA; and 2Cardiology Center, University of Geneva, Geneva, Switzerland
Received 20 August 2010; revised 5 January 2011; accepted 17 January 2011; online publish-ahead-of-print 29 March 2011
Alcohol septal ablation (ASA) was introduced in 1994 as an alternative to septal myectomy for patients with hypertrophic obstructive car-
diomyopathy and symptoms refractory to medical therapy. This procedure alleviates symptoms by producing a targeted, limited infarction of
the upper interventricular septum, resulting in an increase in left ventricular outflow tract (LVOT) diameter, a decrease in LVOT gradient,
and regression of the component of LV hypertrophy that is due to pressure overload. Clinical success, with improvement in symptoms and
reduction in gradient, is achieved in the great majority of patients with either resting or provocable LVOT obstruction. The principal mor-
bidity of the procedure is complete heart block, resulting in some patients in the requirement for a permanent pacemaker. The introduction
of myocardial contrast echocardiography as a component of the ASA procedure has contributed to the induction of smaller myocardial
infarctions with lower dosages of alcohol and, in turn, fewer complications. Non-randomized comparisons of septal ablation and septal
myectomy have shown similar mortality rates and post–procedure New York Heart Association class for the two procedures.
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Introduction
Hypertrophic cardiomyopathy (HCM) is a disease characterized by
idiopathic hypertrophy of the left ventricle (LV). Clinical manifes-
tations include diastolic dysfunction and dysrhythmias. Symptoms
include dyspnoea, angina, lightheadedness, and syncope. Hyper-
trophic cardiomyopathy patients with LV outflow tract (LVOT)
gradients under resting conditions or with provocation (as with
Valsalva manoeuvre or exercise) are classified as having hyper-
trophic obstructive cardiomyopathy (HOCM). Obstruction results
from a combination of interventricular septal hypertrophy, hyper-
dynamic LV contraction, and drag and Venturi forces, creating sys-
tolic anterior motion (SAM) of the anterior leaflet of the mitral
valve (Figure 1). Left ventricular outflow tract obstruction at rest
is observed in 25% of the patients with HCM and is an indepen-
dent predictor of poor prognosis.1,2 In one report, the majority of
patients with HCM had resting or provocable obstruction.3
Although symptoms are effectively alleviated in the majority of
symptomatic HOCM patients by negative inotropic drugs,
namely b-blockers, verapamil, and disopyramide, they are refrac-
tory to medical therapy in 5–10% of the patients.4 Surgical
septal myectomy has been performed for half a century, and
abolishes the gradient and relieves symptoms in the great majority
of patients.5 Some patients, however, have absolute or relative
contraindications to surgery in the form of concomitant medical
conditions, advanced age, or previous cardiac surgery.6,7 In experi-
enced centres, surgical mortality is ,2% in young, otherwise
healthy patients, but is higher in older patients and in those requir-
ing concomitant surgical procedures, such as coronary artery
bypass grafting.8 In 1994, Sigwart9 introduced a catheter treatment
that uses absolute alcohol to induce a relatively small, targeted
myocardial infarction in the septum as an alternative to surgery.
Intracoronary injection of alcohol had been previously employed
for therapy of refractory ventricular tachycardia.10 Injection of
ethanol had caused transmural myocardial necrosis in a canine
model.11 This technique was applied to HOCM after the obser-
vation, in patients with septal hypertrophy, that the LVOT gradient
was transiently reduced during septal artery occlusion by a balloon
catheter. The procedure has gone by a variety of names, including
non-surgical myocardial reduction, transcoronary ablation of septal
hypertrophy, percutaneous transluminal septal myocardial ablation,
and alcohol septal ablation (ASA). Although initially confined to
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Europe and North America, this technique is now being performed
worldwide.12 In the absence of randomized controlled trials com-
paring ASA to medical therapy or septal myectomy, our current
view of the procedure is based on registry data, meta-analyses,
and personal experience.
The procedure
b-Blocker therapy should be discontinued and intravenous fluid
boluses avoided in order to allow for optimal assessment of the
LVOT gradient. Patients receive aspirin and heparin for this intra-
coronary procedure. Because the proximal septal branches of
the left anterior descending (LAD) coronary artery supply the con-
duction system as well as the basal septum (Figure 2), transient
(and, in some cases, sustained) atrioventricular (AV) block is a
common effect of alcohol injection. All patients without perma-
nent devices therefore receive a temporary right ventricular pace-
maker. The use of a flexible screw–in pacemaker electrode may
lower the incidence of pericardial tamponade resulting from
cardiac perforation.13
Although operators at some centres monitor the LVOT
gradient with echocardiography only, most prefer to rely on
intraprocedural haemodynamic measurements, with either
retrograde or (using the transseptal technique) anterograde
catheterization of the LV. Studies have shown that the clinical
success of ASA in patients with provocable obstruction is
comparable to that in patients with obstruction at rest.14,15
Candidacy of patients for ASA should be determined with
exercise rather than pharmacological provocation, since drugs
may produce intracavitary gradients of questionable pathophysio-
logical significance. Since exercise is impractical in the midst of
the ASA procedure, intraprocedural LVOT gradients are pro-
voked instead by administration of a positive inotropic drug
such as isoproterenol or dobutamine or a vasodilator such as
nitroglycerin or amyl nitrite, by induction of extrasystoles with
Figure 2 Schematic diagram of blood supply to cardiac conduction system. The first septal branch of the left anterior descending (LAD)
coronary artery supplies a critical portion of the interventricular conduction system (red oval). AV, atrioventricular; marginal a., marginal
artery; PDA, posterior descending artery; RCA, right coronary artery; SA, sinoatrial. Reproduced, with permission, from Harthorne JW,
Pohost. GM, Electrical therapy of cardiac dysrhythmias. In Levine, HJ (ed) Clinical Cardiovascular Physiology, New York, Grune and Stratton:
1976. pp. 853–882.
Figure 1 End–systolic frame from a left ventriculogram in left
anterior oblique, cranially angulated projection in a patient with
hypertrophic obstructive cardiomyopathy. There is systolic
anterior motion of the anterior leaflet of the mitral valve
(ALMV), which comes into apposition with the interventricular
septum (IVS), associated with a left ventricular outflow tract gra-
dient. Ao, aorta; LA, left atrium; LV, left ventricle.
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programmed stimulation utilizing the temporary pacemaker, or
by the Valsalva manoeuvre.15
Standard coronary angioplasty guiding catheters and guide wires
are used, along with short, small-diameter over–the–wire angio-
plasty balloon catheters. Guidance by myocardial contrast echo-
cardiography (MCE; Figure 3) has proved to be particularly useful
and may influence the interventional strategy in 15–20% of the
cases, by either changing the target vessel or prompting that the
procedure be aborted. In addition, MCE allows higher success
rates despite lower infarct sizes, in turn reducing complication
rates.16,17 Echo contrast or agitated X-ray contrast is injected via
the inflated balloon catheter while transthoracic echocardiography
is performed. This allows for the determination of whether
the opacified myocardium is adjacent to the point at which the
anterior leaflet of the mitral valve comes into contact with the
septum and at which there is maximal flow acceleration. If the ter-
ritory perfused by the contrast agent is not optimal, for example, if
the right side of the interventricular septum is predominantly opa-
cified, alcohol administration is withheld.18 This technique also
serves to delineate any retrograde leakage of contrast or involve-
ment of the myocardium, such as the ventricular free wall or papil-
lary muscles, remote from the target region.17,19,20 Alternatively,
ASA may be guided by the assessment of reduction in LVOT
gradient during transient balloon occlusion of the septal branch.9,21
Alcohol is usually injected into the most proximal accessible
septal branch of the LAD. Once the septal perforator is deemed
suitable, 96% ethanol, 0.5–1.0 mL at a time to a total of
1–3 mL, is injected through the inflated balloon catheter after
analgesia is given for control of chest pain. With greater operator
experience and the use of MCE, there has been a trend towards
using lower dosages of ethanol, without loss of efficacy.21–23
There is considerable variability in the blood supply to the upper
interventricular septum.24 The target septal branch may occasion-
ally originate from the left main coronary artery, an intermediate
or diagonal branch,17 or the posterior descending coronary
artery.25 The haemodynamic objective is a decrease in the gradient
to ,10 mmHg at rest in patients with resting gradients (Figure 4)
or a decrease by .50% of a provocable gradient.25 In some
cases, alcohol is injected into subbranches of the septal artery,
whereas, in others, injection into two or even three septal
branches is required to reduce the gradient.
Length of stay varies considerably among centres performing
ASA. Patients are observed in the cardiac intensive care unit for
24–72 h, with removal of the temporary pacemaker after
24–48 h in the absence of AV block. Patients may then be trans-
ferred to a monitored step-down unit for the remainder of the
hospital stay.
Treatment efficacy
Septal ablation performed by skilled operators at high–volume
centres results in a marked immediate decrease in LVOT gradient
in the great majority (usually ≥80%) of patients.26–31 Pooled
results of published studies on ASA show acute reductions in
the mean resting LVOT gradient from 65 to 17 mmHg and the
mean post-extrasystolic gradient from 125 to 53 mmHg, with per-
sistence of the reduction after 12 months (16 and 32 mmHg,
respectively).32 In addition, there is a significant improvement at
12 months in functional class [New York Heart Association
(NYHA) class 2.9 to 1.2, Canadian Cardiovascular Society (CCS)
class 1.9 to 0.4], peak oxygen consumption (17.8 to 23.6 mL/kg/
min), and exercise capacity (86 to 123 W). At mean 4.6–year
follow–up at one centre, there were progressive decreases in
resting and provoked LVOT gradients; NYHA class had decreased
from 2.8 to 1.2, CCS class had decreased from 2.1 to 1.0, and exer-
cise time had increased from 4.8 to 8.2 min.33 The benefit of ASA
in older patients is similar to that in younger patients.34,35
We consider ASA to be successful if there is improvement by a
least one NYHA or CCS class accompanied by a sustained
reduction in the resting or provoked gradient by ≥50%. Reported
predictors of procedural failure are total peak CK, 1300 U/L and
immediate residual LVOT gradient ≥25 mmHg.36 Repeat pro-
cedures (ASA or septal myectomy) despite initial success are
required because of recurring gradient and symptoms in 9% of
the patients.32 Conversely, ASA has been performed successfully
for residual or recurrent gradients and symptoms after septal
myectomy.36 The annual cardiac mortality rate after ASA was
0.7% in a large study.37
Figure 3 Four-chamber echocardiographic view of area of the
upper septum opacified by alcohol injection (asterisk). LA, left
atrium; LV, left ventricle; RA, right atrium; RV, right ventricle.
Figure 4 Left ventricular (LV), aortic (Ao), and left atrial (LA)
pressures before (left panel) and immediately after (right panel)
alcohol septal ablation.
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Mechanisms of treatment efficacy
Alcohol septal ablation induces well–demarcated myocardial
necrosis surrounding the septal branch.27 Baggish et al.38 found evi-
dence of necrosis of the vascular endothelium as well (Figure 5).
The haemodynamic response to the induced reduction in the
septal myocardium is often triphasic.39,40 Immediately after ASA,
there is a marked reduction in the LVOT gradient. This initial
relief is often followed during the following days by a rise in the
LVOT gradient to 50% of the pre-procedure level, possibly in
relation to recovery from stunning or to oedema caused by the
infarction. Finally, within the following weeks to months, there is
a new decrease in LVOT gradient back to the immediate post-
ablation level. Carasso et al.41 have suggested that ASA induces
changes in both septal and global myocardial mechanics, both of
which contribute to the haemodynamic result. With the acute
decrease in LV systolic pressure, there is also immediate improve-
ment in coronary flow reserve.42
It is believed that long-term benefit results from the creation of
localized septal infarction and scarring, which increase LVOT diam-
eter as a result of septal thinning and ‘therapeutic remodel-
ling.’16,43,44 Serial cardiac magnetic resonance imaging studies
demonstrate an increase in area of the outflow tract over
months, coinciding with the time course of amelioration of symp-
toms.45 There is an increase in LV size, a decrease in LV mass,44–46
and an alteration in septal activation that results in incoordination
of contraction.47 Regression of hypertrophy in areas remote from
the basal septum after ASA indicates that myocardial hypertrophy
is not entirely due to a genetic defect, but rather is in part after-
load–dependent.44,48
After ASA, the degree of mitral regurgitation is lessened,26,27,49
LV end–diastolic pressure falls,26,27 and the left atrium is smaller.26
Furthermore, changes in diastolic function resulting from ASA also
seem to contribute to long-term improvement in haemody-
namics50 and exercise tolerance.49 Improvement in diastolic func-
tion may be due to more favourable load–dependent relaxation,
as well as a reduction in LV stiffness due to regression of
hypertrophy44,49,51–53 and decrease in interstitial collagen
content. There is also normalization of the blood pressure
response to exercise.29 Although studies have demonstrated
improvement in these parameters in most patients, there is con-
siderable individual variability in the response to ASA.
Adverse events
Early mortality (occurring ≤30 days after the procedure) is low,
with a mean value of 1.5% reported,32 similar to that for surgical
myectomy. Causes of early mortality include LAD dissection, ven-
tricular fibrillation, cardiac tamponade, cardiogenic shock, pulmon-
ary embolism, and bradyarrhythmias in patients without
functioning pacemakers. Spontaneous ventricular fibrillation in
the immediate periprocedural period is not frequent (2.2%), and
sustained ventricular tachycardia is unusual.32,54 In patients with
standard risk factors for sudden cardiac death, we consider the pla-
cement of an internal cardioverter–defibrillator (ICD) prior to
ASA. The occasional patient with ventricular tachycardia after
ASA may also be considered for ICD implantation.
The most frequent complication of ASA is complete AV block
requiring permanent pacemaker implantation. The reason for this
lies in the anatomical proximity of the septal perforators to the
conduction system, in particular the right bundle branch.55
Acute, self–terminating complete AV block during the procedure
occurs in approximately half of the patients.26,31,56–58 There is
recovery of AV conduction, usually before the patient reaches
the cardiac intensive care unit, in the great majority of patients.56,57
Disappearance of procedural complete AV block has been
reported as late as 13 days after the procedure.56 Delayed com-
plete AV block may also develop later in patients without previous
procedural complete AV block59 or as a recurrence after recovery
from acute complete AV block. Depending on the definition used,
delayed complete AV block occurs in 1–25% of the cases after a
mean period of 36 h post-procedure and usually requires perma-
nent pacemaker implantation due to persistence of the conduction
defect.57–59 Lawrenz et al.58 obtained electrophysiological record-
ings at the end of ASA procedures and found that delayed AV
block occurred in patients with impaired retrograde AV conduc-
tion. In one study, the use of MCE limited the infarct size and
reduced the need for permanent pacemaker implantation from
17 to 7%.26
We and others implant a pacemaker if the block persists for
.48–72 h. Ultimately, 10% of the patients require permanent
pacemaker implantation after ASA.32 Predictors of subsequent
permanent pacemaker implantation appear to be baseline left
bundle branch block (LBBB), baseline first–degree AV block, pro-
cedural complete AV block, and post–procedure new first–
degree AV block or intraventricular conduction defect.36,57,58,60
Some authors suggest elective permanent pacemaker implantation
prior to ASA in patients with pre–existing LBBB.31
Finally, although concern has been raised about creation of an
arrhythmogenic substrate by ASA,61,62 there is currently no evi-
dence that indicates an increase in incidence of ventricular arrhyth-
mias during follow–up, as assessed by analysis of implantable
cardioverter-defibrillator intervention rates.63,64 Similarly, sudden
death after ASA occurs uncommonly.21,65 A meta–analysis
Figure 5 Gross and microscopic specimens of the interventri-
cular septum from a patient who underwent septal myectomy
after unsuccessful alcohol septal ablation. The myocardium is
yellow, and thus necrotic (left panel). Both myocytes (yellow
arrow) and vascular endothelial cells (black arrow) are devoid
of nuclei, indicating necrosis (right panel). Adapted from
Baggish et al.38 with permission.
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comparing ASA to septal myectomy has shown no difference
between the two procedures in the incidence of ventricular
tachyarrhythmias.66
Comparison to septal myectomy
No randomized controlled trial comparing ASA to surgical myect-
omy has been performed. Although it would be useful to conduct
such a trial in patients whose anatomy is conducive to both pro-
cedures,67 some have calculated that it would be impossible to
enrol enough patients to compare the effects of the two pro-
cedures on survival.68 Evidence from non-randomized trials also
indicates that ASA is similar to myectomy with respect to haemo-
dynamic and functional improvement (Table 1).69–72 In one of
these studies, because patients were assigned to therapy according
to the institutional preference, it was possible to match patients for
age and LVOT gradient.69 At 1–year follow–up, severity of symp-
toms, maximal oxygen consumption, gradient, septal thickness, and
degree of mitral regurgitation were similar for the two interven-
tions. Patients with higher mortality rates after ASA reported by
Ten Cate et al.73 (Table 1) had received higher doses (mean
3.5 mL) of ethanol than are used in the current practice.
Meta-analyses of comparative studies of ASA and septal myec-
tomy have shown no difference in mortality or post–procedure
NYHA class between the two procedures.66,74 A report compar-
ing meta-analyses of 19 ASA and 8 myectomy studies demon-
strated lower all-cause mortality and sudden cardiac death rates
after ASA after adjustment for baseline characteristics, with no
difference in NYHA class.75 All of these studies showed a higher
residual gradient and a higher incidence of permanent pacemaker
implantation after ASA. The general consensus is that in centres
with appropriate expertise, operative risks, haemodynamic
benefits, and initial symptomatic benefits are broadly comparable
with either technique.76
Patient selection
Patient selection for either form of septal reduction therapy,
myectomy or ASA, is based on a careful individual evaluation of
symptoms, associated co-morbidities, and echocardiographic and
angiographic parameters.7,25,77 The primary indication for the pro-
cedures consists of symptoms that interfere substantially with life-
style and which are refractory to optimal medical therapy. Most
candidates are in NYHA heart failure or CCS angina class III or
IV. Selected patients with advanced NYHA or CCS class II symp-
toms (e.g. those with syncope or severe pre-syncope) may also
be considered for the procedures. Candidates have an LVOT gra-
dient of ≥30–50 mmHg at rest or ≥50–60 mmHg with exercise.
Septal wall thickness ,16 mm is considered a contraindication to
either myectomy or ASA because of the concern that the risk of
septal perforation with creation of a ventricular septal defect
may be higher in the absence of marked hypertrophy.
Patients with septal anatomy unfavourable for delivery of alcohol
and those requiring surgery for a co-morbid condition such as
intrinsic mitral valve disease are triaged to septal myectomy.
Mitral regurgitation caused by SAM is invariably associated with a
posteriorly directed jet; if regurgitation is not posteriorly directed,
the mitral apparatus should be examined echocardiographically
with particular care. Surgery is often preferred in younger patients
and in those with severe hypertrophy of the septum (e.g.
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Table 1 Studies comparing efficacy and safely of septal ablation and septal myectomy
Authors Institution n How triaged Efficacy Safety
Nagueh
et al.69
Baylor (ablation),
Mayo Clinic
(myectomy)
41 ablation,
41 myectomy
Institutional preference No difference in NYHA class,
exercise capacity, or
gradient
Death: 2% ablation vs. 0%
myectomy; PPM: 22%
ablation vs. 2%
myectomy
Qin et al.70 Cleveland Clinic 25 ablation,
26 myectomy
Age, co-morbid conditions,
need for concomitant
surgery
No difference in NYHA class;
.50% gradient reduction in
76% ablation vs. 100%
myectomy
No deaths; PPM in 24%
ablation vs. 8%
myectomy
Firoozi
et al.71
St George’s Hospital 20 ablation,
24 myectomy
Age, patient and physician
choice
No difference in NYHA class
or gradient; exercise
capacity better after
myectomy
Death: 5% ablation vs. 4%
myectomy; PPM: 15%
ablation vs. 4%
myectomy
Ralph–
Edwards
et al.72
Toronto General
Hospital
54 ablation,
48 myectomy
Age, patient and physician
choice
NYHA I or II in 41% ablation vs.
72% myectomy
Late death in 11% ablation
vs. 0% myectomy
Sorajja
et al.13
Mayo Clinic 123 ablation,
123 myectomy
Patient choice, co-morbid
conditions
No difference in survival free of
severe symptoms
No difference in mortality;
PPM: 23% ablation vs. 2%
myectomy
Ten Cate
et al.73
Thoraxcenter 91 ablation,
40 myectomy
Patient choice, co-morbid
conditions, need for
concomitant surgery
Not reported Higher rate of cardiac death
or aborted sudden death
after ablation
NYHA, New York Heart Association functional class; PPM, permanent pacemaker. Adapted from Fifer78 with permission.
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≥30 mm). Alcohol septal ablation is usually selected for elderly
patients and those with co-morbid conditions that increase the
risk of surgery. For many patients, both procedures are reasonable
options; the principle of patient autonomy dictates that these
patients should be offered the choice of the two procedures
after a frank and thorough discussion of the relative benefits and
risks.78 Selection criteria for ASA are summarized in Table 2.
Future directions
Since the original description in 1994, the procedure has under-
gone several modifications and improvements that have led to
optimization of the results and minimization of complications,
most importantly the use of MCE and reduction in the dosage of
alcohol. Veselka et al.79 have suggested that the use of MCE with
low mechanical index will result in less bubble destruction and,
as a result, more accurate delineation of the territory supplied
by the septal branch. The use of intracardiac echocardiography
has been introduced as a means of providing continuous intrapro-
cedural imaging of the treated segment of the septum.80,81 Facili-
tation of septal artery cannulation by magnetic navigation has
also been reported.82 Other novelties include the use of polyvinyl
alcohol foam particles, microspheres, absorbable gelatin sponges,
or septal coils as alternatives to alcohol; these techniques may
further reduce the incidence of complete heart block.83–87
Finally, reduction in septal mass by radiofrequency catheter abla-
tion and cryoablation are under investigation.88,89
Conclusion
Although surgical myectomy has set the standard of therapy for
drug-resistant HOCM, ASA is an alternative that may be con-
sidered for many patients. Data indicate that medium–term func-
tional and haemodynamic success of ASA is high and similar to that
of surgery, with the advantage that it may be performed in patients
for whom surgery may be considered unsuitable. Longer–term
follow–up is needed to permit judgement of the durability of
the benefit of ASA. Benefits of ASA in comparison to myectomy
include shorter hospital stay, less pain, and avoidance of compli-
cations associated with surgery and cardiopulmonary bypass.
Nevertheless, ASA has an important learning curve, with poten-
tially serious complications, the most frequent of which is com-
plete AV block requiring permanent pacemaker implantation in
10% of the patients. Although these rates are declining with con-
tinuing experience, the advent of imaging techniques such as MCE,
and the use of lower alcohol dosages, the procedure should be
performed only by experienced operators and on carefully
selected patients. There are no data that indicate that the indi-
cation for performing either ASA or septal myectomy should be
extended to patients with HOCM and no or mild symptoms.
Conflict of interest: none declared.
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